What is A&G Pharmaceutical?
A&G Pharma is a theranostics company dedicated to developing monoclonal antibodies targeting cancer-specific biomarkers for innovative therapeutic and diagnostic products. Their approach focuses on personalized cancer care by engineering therapeutics that selectively address tumor growth while providing FDA-approved companion diagnostics for early detection and treatment monitoring. The company aims to improve patient outcomes through a comprehensive range of medicines and integrated solutions that ensure accessibility and affordability. With a strong foundation in scientific research, AG Pharma partners with healthcare providers to advance cancer detection and treatment.
How much funding has A&G Pharmaceutical raised?
A&G Pharmaceutical has raised a total of $387K across 2 funding rounds:
Debt
$150K
Debt
$237K
Debt (2020): $150K with participation from PPP
Debt (2021): $237K led by PPP
What's next for A&G Pharmaceutical?
The substantial late-stage funding positions A&G Pharmaceutical for accelerated growth and market penetration. This capital infusion is expected to fuel the advancement of their pipeline of monoclonal antibodies and companion diagnostics, potentially leading to expanded clinical trials and commercialization efforts. The company's strategic focus on personalized cancer care and integrated solutions suggests a trajectory aimed at enhancing patient outcomes and solidifying its role in the evolving landscape of oncology treatments.
See full A&G Pharmaceutical company page
